Aims-(1) To investigate the immunohistochemical expression of the multidrug resistance gene (MDR1) product P-glycoprotein in histological samples from 31 hepatocellular carcinomas (HCCs); and (2) to correlate the results with cell proliferation, p53 expression, the disease-free interval, and cumulative patient survival. Methods-C219 (a monoclonal antibody), CM-1 (a polyclonal rabbit anti-human antibody) and PC1O (a monoclonal mouse anti-human antibody) were used to detect expression of P-glycoprotein, p53 and proliferating cell nuclear antigen (PCNA), respectively, by means of the avidin-biotin peroxidase method. Results-Membrane bound positivity for P-glycoprotein was observed in 20 (65%) of the 31 HCCs. Cytoplasmic globular positivity was also seen in some cases. There were no significant associations between expression of P-glycoprotein and cell proliferation (determined by PCNA inimunoexpression and the mitotic count), or p53 expression. Patients with P-glycoprotein positive tumours had a shorter disease-free interval than those with P-glycoprotein negative tumours, and also had a shorter survival time. There was no difference in survival between P-glycoprotein positive patients who had or had not received chemotherapy, suggesting that chemotherapy (mainly mitomycin-C ) did not affect survival in these patients. Conclusions-Expression of P-glycoprotein in HCCs is associated with a shorter disease-free interval and shorter survival time. As expression of P-glycoprotein was not associated with cell proliferation or expression of p53, its effect on disease progression and survival seems to be independent of these factors.
P-glycoprotein positive tumours had a shorter disease-free interval than those with P-glycoprotein negative tumours, and also had a shorter survival time. There was no difference in survival between P-glycoprotein positive patients who had or had not received chemotherapy, suggesting that chemotherapy (mainly mitomycin-C ) did not affect survival in these patients. Conclusions-Expression of P-glycoprotein in HCCs is associated with a shorter disease-free interval and shorter survival time. As expression of P-glycoprotein was not associated with cell proliferation or expression of p53, its effect on disease progression and survival seems to be independent of these factors. P-glycoprotein is a 170 kilodalton, membrane bound glycoprotein encoded by the multidrug resistance (MDR 1) gene' 2 andfunctions as an ATP dependent pump propelling drugs and cytostatics out of the cell cytoplasm. Because of its involvement in drug resistance, the expression of P-glycoprotein has been studied in several different neoplasms and increased P-glycoprotein expression has been found in several epithelial tumours, such as those of the colon and breast." In breast carcinomas expression of P-glycoprotein has been associated with p53 expression and cell proliferation, as evaluated by the Ki67 index.5 P-glycoprotein expression has also been associated with a shorter disease-free interval in carcinomas of the breast, colon and kidney. 4 78 Expression of P-glycoprotein has been studied previously in liver cells and in hepatocellular carcinomas (HCCs). In non-neoplastic liver P-glycoprotein is expressed in the biliary canalicular pole of hepatocytes3 and in epithelial cells lining the biliary ducts; 60-70 % of HCCs are P-glycoprotein positive.3 9 Activation of the MDR1 gene in hepatic tissues has been studied extensively in animal models; several rodent hepatocarcinogenesis models show that enhanced MDR1 expression is associated with the later stages of carcinogenesis.'°I n this study we investigated P-glycoprotein expression in 31 patients with HCC. The aim of the investigation was to compare P-glycoprotein expression with the disease-free interval, cumulative survival and other clinical parameters.
Methods
Sections from 31 HCCs (from 13 men and 18 women) resected between 1983 and 1993 were retrieved from the files of the Department of Pathology, Oulu University Hospital. All of the material had been fixed in 10% neutral formalin and embedded in paraffin wax. In all cases the diagnosis had been based on conventional light microscopy, according to the criteria of theWorld Health Organisation." Table 1 slides in 20 % fetal calf serum in phosphate buffered saline (PBS) for 20 minutes. Sections were pretreated in a microwave oven in 10 mM citric acid monohydrate, pH 6.0, for three minutes and were then incubated with the primary monoclonal antibody (C219; Signet Laboratories, Dedham, Massachusetts, USA) (diluted 1 in 20) directed against P-glycoprotein for three hours. The biotinylated secondary anti-mouse antibody (Dako, Glostrup, Denmark) (diluted 1 in 300) was applied, followed by the avidin-biotin peroxidase complex (Dako). Normal liver served as an internal positive control.
To detect p53 expression, sections were first incubated overnight at 4°C with a polyclonal rabbit anti-human p53 antibody (CM-i; Novocastra Laboratories, Newcastle upon Tyne, UK) diluted 1 in 1000.14 A biotinylated anti-rabbit immunoglobulin (diluted 1 in 100; Dako) and the avidin-biotin peroxidase complex were then added. Sections from a lung carcinoma previously shown to be strongly positive for p53 served as a positive control.14 A mouse monoclonal IgG2a primary antibody (PC 10; Dako) was used to detect proliferating cell nuclear antigen (PCNA). The sections were incubated with the primary antibody (diluted 1 in 50) for one hour, followed by a secondary rabbit anti-mouse antibody (diluted 1 in 200) (Dako) and the avidin-biotin peroxidase complex. A lymph node with follicular hyperplasia served as positive control.
In all cases sections were rinsed stringently, with several changes of PBS between each stage. Diaminobenzidine was used as the chromogen. Sections were were lightly counterstained with haematoxylin and mounted with Eukitt (Kindler, Freiburg, Germany). For negative controls non-immune mouse or rabbit serum replaced the primary antibodies in all cases.
Expression of P-glycoprotein and p53 was scored as follows: -= negative; + = < 10 % tumour cells positive; + + = s 30 % tumour cells positive; + + + = >30 % tumour cells positive. In the case of PCNA, the percentage of positively stained cells was evaluated in each section. P-glycoprotein immunostaining was mainly localised to the membrane, although cytoplasmic staining was seen in some sections. PNCA and p53 immunoreactivity was nuclear. Cell proliferation was also assessed by counting the number of mitotic figures per 10 high power fields.
STATISTICAL ANALYSIS
Comparisons between groups were made using the two-tailed Student's t test. The significance of associations was determined using Fisher's exact probability test and correlation analysis. Survival data were analysed using the KaplanMeyer method. The difference between survival in different groups was analysed using the log rank test. Probability values of less than 0.05 were considered significant. Results P-glycoprotein was expressed in 20 (65 %) of the 31 HCCs. Immunoreactivity was mainly confined to the cell membrane, but in some Seven patients also had liver cirrhosis, of whom five had P-glycoprotein positive tuin mours (p = 0.49, Fisher's exact test). There was no statistically significant association between P-glycoprotein expression and long term medication for conditions other than HCC-for example, for late onset diabetes, high blood pressure, heart failure, bronchial asthma, and others (data not shown).
Discussion
Previous studies have reported that P-glycoprotein positive breast, colon or renal tumours are associated with a shorter diseasefree interval than their P-glycoprotein negative counterparts.47 8 Our results suggest that this is also true for patients with HCC ( fig 3) . Although, in the present study, the difference in survival time between patients with and without P-glycoprotein positive tumours did not reach statistical significance, P-glyco- Follow up (months) Figure 4 Kaplan-Meyer curve showing the difference in the disease-free interval in P-glycoprotein positive and negative tumours. Patients with P-glycoprotein positive tumo had a significantly shorter disease-free interval (p < 0. 05, log rank test). obtained at surgery from patients who had not undergone preoperative chemotherapy. In some cases chemotherapy may induce P-glycoprotein expression,2 which may then have an adverse effect on prognosis.
Twelve patients underwent postoperative chemotherapy. All patients received mitomycin-C; two patients subsequently received epirubicin and one doxorubicin. To test whether chemotherapy influenced postoperative survival, we compared P-glycoprotein expression in patients who did and did not undergo chemotherapy. No difference in the survival time was found, suggesting that chemotherapy did not affect prognosis in patients with P-glycoprotein positive tumours. The reason for this may be because mitomycin-C was the main chemotherapeutic agent used in the present study and has been found to be insensitive to drug resistance induced by MDR1 in vitro."5 P-glycoprotein immunostaining was mainly confined to the cell membrane in HCCs, a pattern which was also seen in the adjacent non-neoplastic liver cells. Intracellular globular immunostaining was observed in some cases, and its perinuclear location suggested that P-glycoprotein was present in the Golgi apparatus, confirming previous electron microscopy studies. 1 Chin et al6 reported that mutant p53 can activate the MDR1 promoter and Charpin et at found that expression of P-glycoprotein was associated with p53 expression and with a high proliferation rate in breast cancer. In contrast, however, De Angelis et al"' found no association between expression of p53 and P-glycoprotein in colorectal carcinomas. This was also the case in the present study, suggesting that expression of p53 and cell proliferation have no effect on P-glycoprotein expression in HCC.
In conclusion, expression of P-glycoprotein in HCCs is associated with a shorter diseasefree interval and shorter survival time. As expression of P-glycoprotein was not associated with cell proliferation or expression of p53, its effect on disease progression and survival seems to be independent of these factors.
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